Lyell Immunopharma, Inc. Stock Issued During Period, Shares, Conversion of Convertible Securities
Lyell Immunopharma, Inc. (LYEL) reported Stock Issued During Period, Shares, Conversion of Convertible Securities of 194.47 million shares for the 6-month period ending 2021-06-30, per its 10-Q filed 2021-08-12.
Discontinued › Shareholders' Equity
us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities · last filed 2021-08-12
- 2021-06-30: Stock Issued During Period, Shares, Conversion of Convertible Securities 6 month 194.47M shares.
| Period end | Stock Issued During Period, Shares, Conversion of Convertible Securities 6 month |
|---|---|
| 2021-06-30 | 194.47M shares 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |